Charles Schwab Investment Management Inc. Raises Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Charles Schwab Investment Management Inc. boosted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 261,888 shares of the company’s stock after buying an additional 6,611 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Enliven Therapeutics were worth $5,892,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ELVN. China Universal Asset Management Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after purchasing an additional 1,275 shares during the last quarter. Verition Fund Management LLC bought a new position in Enliven Therapeutics in the third quarter worth about $271,000. SG Americas Securities LLC lifted its position in shares of Enliven Therapeutics by 66.1% during the fourth quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock valued at $374,000 after buying an additional 6,616 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after buying an additional 3,518 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth approximately $559,000. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ELVN shares. BTIG Research began coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. HC Wainwright increased their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $38.75.

Enliven Therapeutics Stock Up 6.5 %

Shares of Enliven Therapeutics stock opened at $22.46 on Tuesday. The company has a 50 day moving average price of $21.32 and a 200 day moving average price of $23.79. The firm has a market capitalization of $1.10 billion, a P/E ratio of -11.82 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52 week low of $15.96 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. As a group, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $325,520. The trade was a 7.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,784 shares of company stock valued at $1,610,375 in the last ninety days. Company insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.